XOMA TECHNOLOGY LTD. Patent applications |
Patent application number | Title | Published |
20160015809 | M-CSF SPECIFIC MONOCLONAL ANTIBODY AND USES THEROF - M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease. | 01-21-2016 |
20150308988 | Antibody Coformulations - This invention relates to stable formulations of multiple antibodies comprising a plurality of antibodies and an effective amount of a succinate buffer wherein the pH of the formulation is between about 4.5 and about 7.0. | 10-29-2015 |
20150110783 | ANTAGONIST ANTI-CD40 ANTIBODY PHARMACEUTICAL COMPOSITIONS - Stable liquid pharmaceutical compositions comprising an antagonist anti-CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and an amount of arginine-HCl sufficient to render the liquid composition near isotonic. The stable liquid antagonist anti-CD40 antibody-containing pharmaceutical compositions of the invention find use in methods for treating proliferative diseases and diseases having an autoimmune and/or inflammatory component. | 04-23-2015 |
20150086991 | USES OF ANTI-CD40 ANTIBODIES - Methods for treating a human patient for a cancer or pre-malignant condition that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for FcγRIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for FcγRIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with a cancer or pre-malignant condition that is treatable with an anti-CD40 antibody and which is refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having a cancer or pre-malignant condition that is refractory to treatment with rituximab (Rituxan®), are also provided. | 03-26-2015 |
20140255391 | METHODS FOR THE TREATMENT OF IL-1BETA RELATED DISEASES - Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof. | 09-11-2014 |
20140242090 | METHODS FOR THE TREATMENT OF IL-1BETA RELATED CONDITIONS - Disclosed are methods and materials for inhibiting (e.g., treating or preventing) uveitis in a subject, including treatment refractory uveitis, using anti-IL-1β binding molecules (e.g., IL-1β binding antibodies or binding fragment thereof). | 08-28-2014 |
20140242071 | M-CSF SPECIFIC MONOCLONAL ANTIBODY AND USES THEREOF - M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease. | 08-28-2014 |
20140148584 | EPHB3-SPECIFIC ANTIBODY AND USES THEREOF - EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer. | 05-29-2014 |
20140030738 | SOLUBLE HUMAN M-CSF RECEPTOR AND USES THEREOF - Soluble human M-CSF receptor is provided, along with pharmaceutical compositions containing such receptor, kits containing a pharmaceutical composition, and methods of diagnosing and treating diseases and disorders associated with M-CSF such as bone loss in a subject afflicted with an osteolytic disease. | 01-30-2014 |
20140023644 | Antibodies Specific for TGF-Beta - The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGFβ), including TGFβ1, TGFβ2 and TGFβ3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGFβ expression. | 01-23-2014 |
20140017249 | METHODS FOR IMPROVEMENT OF BETA CELL FUNCTION - Disclosed are methods for improvement of beta cell function in a subject using an anti-IL-1β antibody or fragment thereof. | 01-16-2014 |
20140004125 | IL-1BETA BINDING ANTIBODIES AND FRAGMENTS THEREOF | 01-02-2014 |
20130230528 | METHODS FOR DIAGNOSIS AND TREATMENT OF PROLIFERATIVE DISORDERS MEDIATED BY CD40 SIGNALING - Methods for identifying subjects having a cancer or pre-malignant condition that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing neoplastic cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent. | 09-05-2013 |
20130067721 | FLEXIBLE MANUFACTURING SYSTEM - A flexible, multi-product, multi-technology, expandable facility for manufacturing products, such as biologicals, pharmaceuticals, or chemicals, and manufacturing processes using elements of such a facility. | 03-21-2013 |
20120315282 | Antibodies Specific for TGF-Beta - The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGFβ), including TGFβ1, TGFβ2 and TGFβ3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGFβ expression. | 12-13-2012 |
20120178126 | METHODS AND MATERIALS FOR INCREASING EXPRESSION OF RECOMBINANT POLYPEPTIDES - The present invention provides novel methods and materials for increasing the expression of recombinant polypeptides. Methods and materials of the invention allow increased expression of transcription units that include recombinant DNA sequences which encode polypeptides of interest. The present invention provides expression vectors which contain multiple copies of a transcription unit encoding a polypeptide of interest separated by at least one selective marker gene and methods for sequentially transforming or transfecting host cells with expression vectors to increase transcription unit dosage and expression. | 07-12-2012 |
20120171226 | ANTIBODIES TO HIGH MOLECULAR WEIGHT MELANOMA ASSOCIATED ANTIGEN - The present disclosure relates to anti-high molecular weight melanoma associated antigen (HMW-MAA) antibodies which bind to human HMW-MAA. Such antibodies may be used to treat diseases or disorders characterized by expression of HMW-MAA including cancer, for example, melanoma, basal cell carcinoma, ALL or AML. | 07-05-2012 |
20120014967 | IL-1BETA BINDING ANTIBODIES AND FRAGMENTS THEREOF - An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1β binding polypeptide. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency. | 01-19-2012 |
20120014966 | METHODS FOR THE TREATMENT OF IL-1BETA RELATED CONDITIONS - Disclosed are methods and materials for inhibiting (e.g., treating or preventing) uveitis in a subject, including treatment refractory uveitis, using anti-IL-1β binding molecules (e.g., IL-1β binding antibodies or binding fragment thereof). | 01-19-2012 |
20120010101 | NOVEL TRIPLE TAG SEQUENCES AND METHODS OF USE THEREOF - The present disclosure relates to novel triple tag sequences that may comprise a 6× histidine tag, a c-myc tag and a V5 tag. The present disclosure also provides polynucleotides, proteins, vectors and host cells that comprise the triple tag sequence of the present disclosure, including libraries of such polynucleotides, proteins, vectors and host cells. The novel triple tag sequences of the present disclosure may be used in phage display vectors and phage libraries and in methods for detection, screening, capture, purification, quantitation, and/or recovery of proteins of interest to which they are linked. Proteins of interest include antibodies such as single chain antibodies, single chain antibodies, and Fab fragments of antibodies or peptides such as non-antibody peptides. | 01-12-2012 |
20120005127 | METHODS FOR IMPROVEMENT OF BETA CELL FUNCTION - Disclosed are methods for improvement of beta cell function in a subject using an anti-IL-1β antibody or fragment thereof. | 01-05-2012 |
20120003226 | METHODS FOR TREATING OR PREVENTING IL-1BETA RELATED DISEASES - Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, decreased insulin production, hyperglycemia, hypoinsulinemia, metabolic syndrome, Type 1 diabetes and obesity, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof. | 01-05-2012 |
20110319598 | METHODS AND MATERIALS FOR DETERMINING ISOELECTRIC POINT - The present disclosure relates to methods and materials for determining an isoelectric point for a protein including, for example, a binding molecule such as an antibody. The isoelectric points may be used in methods for the preparation of proteins. Such methods may comprise identifying amino acid residues that are exposed on the surface of the protein in a sequence of amino acid residues of the protein, assigning a pKa value to the surface exposed amino acid residues, and calculating the isoelectric point of the protein from the pKa values assigned to the surface exposed amino acid residues. The methods of the present disclosure may be used for selecting and utilizing a buffer for purification of a protein, preparing a protein formulation, purifying a protein and/or stabilizing a protein in solution. | 12-29-2011 |
20110307439 | METHODS AND APPARATUS FOR DISPLAYING PREDICTIONS ASSOCIATED WITH AN ALPHABETIC STRING - The present disclosure provides methods and apparatus for displaying an alphabetic string representing an amino acid sequence of an antibody in association with predicted characteristics of certain sites in the antibody. In an embodiment, a process causes a web based application server to receive an alphabetic string from a client device indicative of an amino acid sequence. The server then predicts sites in the amino acid sequence likely to be associated with certain chemical properties such as deamidation, glycosylation, oxidation, proteolysis, and isomerization. The server may also predict other characteristics such as domain boundaries, binding sites, hydrophobicity levels, surface exposures, etc. The server then sends data to the client device indicative of the predicted sites and characteristics, so that the client device can display the alphabetic string indicative of the amino acid sequence with a graphical indication of the position of each predicted chemical property (e.g., with a semitransparent glyph over the associated alphabetic character). | 12-15-2011 |
20110274692 | Screening Methods - The present invention provides polypeptide binding agents, e.g. antibodies, that exhibit the ability to kinetically modulate the binding and signaling of biological signaling complexes, e.g., receptor-ligand complexes; methods of identifying such polypeptide binding agents, methods of making such polypeptide binding agents, compositions comprising such polypeptide binding agents, and methods of using such polypeptide binding agents. | 11-10-2011 |
20110258837 | FLEXIBLE MANUFACTURING SYSTEM - A flexible, multi-product, multi-technology, expandable facility for manufacturing products, such as biologicals, pharmaceuticals, or chemicals, and manufacturing processes using elements of such a facility. | 10-27-2011 |
20110224102 | Eukaryotic signal sequences for polypeptide expression and polypeptide display libraries - The present invention generally relates to methods and compositions for expressing proteins or polypeptides in prokaryotic hosts using eukaryotic signal sequences. | 09-15-2011 |
20110189172 | METHODS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS - Disclosed are compositions and methods for the treatment and/or prevention of rheumatoid arthritis, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof. | 08-04-2011 |
20110150760 | PRLR-Specific Antibody and Uses Thereof - PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer. | 06-23-2011 |
20110118447 | METHODS AND MATERIALS FOR TARGETED AFFINITY ENHANCEMENT - The present disclosure relates to materials and methods for enhancing the binding affinity of antibodies by introducing a number of targeted amino acid changes in antibody variable domains. The present disclosure provides novel methods of flowcharted amino acid change cycles, of identifying residues as members of unique proximity groups and of determining the degree of conspicuousness of amino acid residues in antibody variable regions. The disclosed methods are useful for the selection of variable region amino acid residues that are candidates for change to produce antibody variable domains with enhanced affinity for their binding partners. | 05-19-2011 |
20110118131 | METHODS AND MATERIALS FOR TARGETED MUTAGENESIS - The present disclosure relates to methods and materials for mutagenesis, including for the generation of novel or improved proteins and libraries or arrays of mutant proteins or nucleic acids encoding such mutant proteins. | 05-19-2011 |
20110076284 | Novel Modulators - Antibodies that modulate insulin receptor signaling are provided. | 03-31-2011 |
20110076279 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING - Vascular endothelial growth factor (VEGF) overexpression is associated with a variety of conditions involving aberrant angiogenesis. Disclosed herein are fully human antibodies that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling Based on their ability to inhibit VEGF signaling, the antibodies disclosed herein may be used to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro. | 03-31-2011 |
20110039722 | LIBRARIES, ARRAYS AND THEIR USES FOR TARGETED AFFINITY ENHANCEMENT - The present disclosure relates to methods and materials for enhancing the binding affinity of an antibody by means of generating a library or an array of targeted amino acid changes (e.g., mutations) at one or more positions in an antibody variable domain. The present disclosure relates to libraries or arrays and their uses for enhancing antibody affinity. The present disclosure relates to methods and materials for mutagenesis, including for the generation of novel or improved antibody variable domains and libraries or arrays of mutant antibody variable domains or nucleic acids encoding such mutant or modified variable domains. | 02-17-2011 |
20110038859 | METHODS FOR THE TREATMENT OF IL-1BETA RELATED DISEASES - Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof. | 02-17-2011 |
20110002934 | USES OF ANTI-CD40 ANTIBODIES - This invention relates to new uses of anti-CD40 antibodies in the treatment of diseases or conditions associated with neoplastic B-cell growth in particular use of anti-CD40 antibodies in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). The invention is particularly useful for the treatment of patients who have previously been administered (i) CHOP, (ii) the chimeric anti-CD20 monoclonal antibody rituximab, or (iii) combination therapy with CHOP and rituximab. | 01-06-2011 |
20100316651 | CARDIOVASCULAR RELATED USES OF IL-1BETA ANTIBODIES AND BINDING FRAGMENTS THEREOF - Disclosed are methods for the reduction, prevention or treatment of cardiovascular events and/or cardiovascular diseases, including acute cardiovascular disease or chronic cardiovascular disease using anti-IL-1β binding molecules (e.g., IL-1β binding antibodies and fragments thereof). The present disclosure also relates to methods for prevention or treatment of cardiovascular events and/or cardiovascular diseases, including by reducing a cardiovascular event or disease. | 12-16-2010 |
20100303807 | METHODS FOR THE TREATMENT OF IL-1BETA RELATED DISEASES - Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof. | 12-02-2010 |
20100184612 | NOVEL TRIPLE TAG SEQUENCE AND METHODS OF USE THEREOF - The present disclosure relates to novel triple tag sequences that may comprise a 6× histidine tag, a c-myc tag and a V5 tag. The present disclosure also provides polynucleotides, proteins, vectors and host cells that comprise the triple tag sequence of the present disclosure, including libraries of such polynucleotides, proteins, vectors and host cells. The novel triple tag sequences of the present disclosure may be used in phage display vectors and phage libraries and in methods for detection, screening, capture, purification, quantitation, and/or recovery of proteins of interest to which they are linked. Proteins of interest include antibodies such as single chain antibodies, single chain antibodies, and Fab fragments of antibodies or peptides such as non-antibody peptides. | 07-22-2010 |
20100099123 | Soluble Human M-CSF Receptor and Uses Thereof - Soluble human M-CSF receptor is provided, along with pharmaceutical compositions containing such receptor, kits containing a pharmaceutical composition, and methods of diagnosing and treating diseases and disorders associated with M-CSF such as bone loss in a subject afflicted with an osteolytic disease. | 04-22-2010 |
20100092464 | M-CSF-Specific Monoclonal Antibody and Uses Thereof - M-CSF-specific RX1-based or RX-I derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in or remodeling in a subject afflicted with an osteoblastic or osteolytic disease. | 04-15-2010 |
20100061998 | IL-1BETA BINDING ANTIBODIES AND FRAGMENTS THEREOF - An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1β binding polypeptide. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency. | 03-11-2010 |
20100055110 | IL-1BETA BINDING ANTIBODIES AND FRAGMENTS THEREOF - An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1β binding polypeptide. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency. | 03-04-2010 |
20100009857 | Eukaryotic signal sequences for polypeptide expression and polypeptide display libraries - The present invention generally relates to methods and compositions for expressing proteins or polypeptides in prokaryotic hosts using eukaryotic signal sequences. | 01-14-2010 |
20090324604 | M-csf specific monoclonal antibody and uses thereof - M-CSF-specific antibody RX1 is provided, along with pharmaceutical compositions containing antibody RX1, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease. | 12-31-2009 |
20090311257 | HUMAN ANTIBODIES SPECIFIC FOR GASTRIN MATERIALS AND METHODS - The present invention relates to materials and methods for human antibodies specific for the peptide hormone gastrin and uses of these antibodies in the treatment of subjects having cancer and other conditions or disorders related to gastrin expression. | 12-17-2009 |
20090304706 | ANTAGONIST ANTI-CD40 ANTIBODY PHARMACEUTICAL COMPOSITIONS - Stable liquid pharmaceutical compositions comprising an antagonist anti-CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and an amount of arginine-HCl sufficient to render the liquid composition near isotonic. The stable liquid antagonist anti-CD40 antibody-containing pharmaceutical compositions of the invention find use in methods for treating proliferative diseases and diseases having an autoimmune and/or inflammatory component. | 12-10-2009 |
20090246831 | Methods for Recombinant Peptide Production - The present invention provides improved methods for the production of recombinant peptides from bacterial cells. | 10-01-2009 |
20090246210 | IL-1Beta Binding Antibodies and Binding Fragments thereof - An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 26 and SEQ ID NO: 11, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency. | 10-01-2009 |
20090246208 | METHODS FOR PREVENTING AND TREATING CANCER METASTASIS AND BONE LOSS ASSOCIATED WITH CANCER METASTASIS - Methods for preventing and treating osteolysis, cancer metastasis and bone loss associated with cancer metastasis by administering an M-CSF-antagonist in combination with a therapeutic agent to a subject are provided. | 10-01-2009 |
20090214568 | Method of Treating or Preventing an IL-1 Related Disease or Condition - Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1β binding antibody or IL-1β binding fragment thereof. An IL-1β binding antibody or IL-1β binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO: 15 and SEQ ID NO: 11, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1β binding polypeptide. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency. | 08-27-2009 |
20090214545 | Method of Treating or Preventing an IL-1 Related Disease or Condition - Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1β binding antibody or IL-1β binding fragment thereof. An IL-1β binding antibody or IL-1β binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO: 15 and SEQ ID NO: 11, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1β binding polypeptide. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency. | 08-27-2009 |
20090202531 | USES OF ANTI-CD40 ANTIBODIES - Methods for treating a human patient for an inflammatory or autoimmune disease that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for FcγRIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for FcγRIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with an inflammatory or autoimmune disease that is treatable with an anti-CD40 antibody and which is non-responsive or refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having an inflammatory or autoimmune disease that is non-responsive or refractory to treatment with rituximab (Rituxan®), are also provided. The methods of the present invention find use in treatment of inflammatory diseases and autoimmune diseases that are associated with CD40-expressing cells. These methods are particularly advantageous with respect to inflammatory diseases and autoimmune diseases that are associated with cells expressing both CD40 and CD20, as the methods enable the treatment of patients having an inflammatory or autoimmune disease that is non-responsive or refractory to therapy with other therapeutic agents such as anti-CD20 antibodies. | 08-13-2009 |
20090142261 | EPHB3-Specific Antibody and Uses Thereof - EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer. | 06-04-2009 |
20090041773 | METHODS FOR DIAGNOSIS AND TREATMENT OF PROLIFERATIVE DISORDERS MEDIATED BY CD40 SIGNALING - Methods for identifying subjects having a cancer or pre-malignant condition that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing neoplastic cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent. | 02-12-2009 |
20080292620 | PRLR-Specific Antibody and Uses Thereof - PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer. | 11-27-2008 |
20080274118 | Methods for Diagnosis and Treatment of Diseases Having an Autoimmune and/or Inflammatory Component - Methods for identifying subjects having an inflammatory disease and/or autoimmune disease that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent. | 11-06-2008 |
20080241126 | Nucleic acids encoding Human Engineered heavy and light chain variable region sequences to Ep-CAM - Human engineered anti-Ep-CAM antibodies and various uses therefore are disclosed. These human engineered anti-Ep-CAM antibodies have high affinity binding to Ep-CAM with low immunogenicity. | 10-02-2008 |
20080233118 | Uses Of Antibody To M-Csf - Methods of using M-CSF antibodies to treat macrophage-associated diseases including atherosclerosis and HIV are provided. | 09-25-2008 |
20080214411 | Eukaryotic signal sequences for polypeptide expression and polypeptide display libraries - The present invention generally relates to methods and compositions for expressing proteins or polypeptides in prokaryotic hosts using eukaryotic signal sequences. | 09-04-2008 |